David Hollenback Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

11/2006

Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Hollenback Research Topics

Disease

4	Neoplasms (Cancer) 04/2014 - 10/2003
3	Fibrosis (Cirrhosis) 11/2023 - 10/2020
2	Liver Diseases (Liver Disease) 11/2023 - 10/2020
2	Inflammation (Inflammations) 11/2023 - 10/2020
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 10/2020
1	Hepatocellular Carcinoma (Hepatoma) 02/2024
1	Fatty Liver 02/2024
1	Sclerosing Cholangitis 11/2023
1	Cholestasis 11/2023
1	Hypertriglyceridemia 01/2022
1	Alcoholic Fatty Liver 10/2020
1	Body Weight (Weight, Body) 04/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2014
1	Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy) 08/2008
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2006
1	Leukemia 08/2006
1	Lymphoma (Lymphomas) 07/2005
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2005
1	Carcinogenesis 10/2003

Drug/Important Bio-Agent (IBA)

4	2-acylglycerophosphate acyltransferaseIBA 11/2006 - 10/2003
2	cilofexorIBA 02/2024 - 11/2023
2	LipidsIBA 01/2022 - 10/2020
2	Choline (Choline Chloride)IBA 01/2022 - 10/2020
2	Protein Isoforms (Isoforms)IBA 08/2006 - 10/2003
2	CT-32228IBA 08/2006 - 07/2005
1	PX-102IBA 02/2024
1	Bile Acids and Salts (Bile Acids)IBA 11/2023
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 11/2023
1	C.I. direct red 80IBA 11/2023
1	Hydroxyproline (4 Hydroxyproline)IBA 11/2023
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 11/2023
1	saroglitazarIBA 01/2022
1	lanifibranorIBA 01/2022
1	firsocostatIBA 01/2022
1	seladelparIBA 01/2022
1	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acidIBA 01/2022
1	resmetiromIBA 01/2022
1	Acetyl-CoA CarboxylaseIBA 01/2022
1	Fenofibrate (CiL)FDA LinkGeneric 01/2022
1	Thyroid Hormone Receptors beta (TR beta)IBA 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 10/2020
1	ProcollagenIBA 10/2020
1	Phosphotransferases (Kinase)IBA 04/2014
1	2- hydroxy- 1- (2- ((9- (4- methylcyclohexyl)- 9H- pyrido(4',3'- 4,5)pyrrolo(2,3- d)pyrimidin- 2- yl)amino)- 7,8- dihydro- 1,6- naphthyridin- 6(5H)- yl)ethanoneIBA 04/2014
1	LeptinIBA 08/2008
1	Imatinib Mesylate (Gleevec)FDA Link 11/2006
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2006
1	Proteins (Proteins, Gene)FDA Link 08/2006
1	EnzymesIBA 08/2006
1	ThymidineIBA 07/2005
1	Monoclonal AntibodiesIBA 07/2005
1	CaspasesIBA 07/2005
1	TriazinesIBA 10/2003
1	Phosphatidic Acids (Phosphatidic Acid)IBA 10/2003
1	DiaminesIBA 10/2003

Therapy/Procedure

4	Therapeutics 01/2022 - 10/2003